BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.

ABSTRACT:

Background

BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported.

Methods

We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21).

Results

The heterogeneity between the published estimates was high (BRCA1: I² = 30%, BRCA2: I² = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs

SUBMITTER: Nyberg T 

PROVIDER: S-EPMC8979955 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature